Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dactinomycin

FDA-approved product (injectable, injection), marketed as Cosmegen, Dactinomycin.

Registered studies
50+
Lab records
1
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Dactinomycin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Kidney Wilms tumor
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Actinomycines
FDA pharmacologic class
Actinomycin FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA95.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli52.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae56.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 1 of 1 lab record
Open Dactinomycin in ChEMBL Registered studies below
Show the 1 laboratory record, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dactinomycin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

    NCT07466316 · start 2026-07-14

    Registered record
    Registry ID
    NCT07466316
    Conditions
    Rhabdomyosarcoma
    Interventions
    Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Bone Scan; Computed Tomography; Cyclophosphamide; Dactinomycin; Irinotecan Hydrochloride; Lumbar Puncture; Lymph Node Biopsy; Magnetic Resonance Imaging; Positron Emission Tomography; Radiation Therapy; Resection; Survey Administration; Vincristine Sulfate; Vinorelbine Tartrate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2026-07-14
    Completion
    2031-03-31
    Enrolment
    342

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhabdomyosarcoma
    InterventionBiospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Bone Scan +13 more
    PhasePhase 3
    Registry statusRecruiting

  • Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes

    NCT07194044 · start 2026-02-05

    Registered record
    Registry ID
    NCT07194044
    Conditions
    Metastatic Ewing Sarcoma
    Interventions
    Vincristine; Doxorubicin; Cyclophosphamide; Ifosfamide; Actinomycin; Irinotecan; Cabozantinib; Topotecan; Temozolomide; Etoposide; Liposomal doxorubicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2026-02-05
    Completion
    2030-10
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Ewing Sarcoma
    InterventionVincristine; Doxorubicin; Cyclophosphamide; Ifosfamide +7 more
    PhasePhase 1
    Registry statusRecruiting

  • A Clinical Study on the Efficacy and Safety of All-trans Retinoic Acid Combined With VAC Regimen in the Treatment of Intermediate-to-high-risk Rhabdomyosarcoma

    NCT07355855 · start 2026-01

    Registered record
    Registry ID
    NCT07355855
    Conditions
    Rhabdomyosarcoma
    Interventions
    ATRA+VAC; ATRA+VAC+Anlotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-01
    Completion
    2029-01
    Enrolment
    106

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhabdomyosarcoma
    InterventionATRA+VAC; ATRA+VAC+Anlotinib
    PhasePhase 2
    Registry statusNot yet recruiting

  • A Single-Arm Study on the Efficacy of Sequential Chemoradiotherapy Followed by Surgery in Adult Nasal and Paranasal Sinus Rhabdomyosarcoma

    NCT07449949 · start 2025-10-30

    Registered record
    Registry ID
    NCT07449949
    Conditions
    ORR; PFS; OS
    Interventions
    VMAT
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Enrolling by invitation
    Start
    2025-10-30
    Completion
    2030-12-30
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionORR; PFS; OS
    InterventionVMAT
    PhaseNot recorded
    Registry statusEnrolling by invitation

  • Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

    NCT06647953 · start 2025-03-21

    Registered record
    Registry ID
    NCT06647953
    Conditions
    Pleuropulmonary Blastoma
    Interventions
    Biospecimen Collection; Biospecimen Collection; Bone Scan; Computed Tomography; Cyclophosphamide; Dactinomycin; Dexrazoxane; Doxorubicin; Echocardiography Test; Ifosfamide; Magnetic Resonance Imaging; Multigated Acquisition Scan; Patient Observation; Positron Emission Tomography; Topotecan; Ultrasound Imaging; Vincristine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-03-21
    Completion
    2029-03-31
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPleuropulmonary Blastoma
    InterventionBiospecimen Collection; Biospecimen Collection; Bone Scan; Computed Tomography +13 more
    PhasePhase 3
    Registry statusRecruiting

  • Embryonal Tumor With Multilayered Rosettes

    NCT06861244 · start 2025-03-06

    Registered record
    Registry ID
    NCT06861244
    Conditions
    Embryonal Tumor With Multilayered Rosettes; Embryonal Tumor With Multilayered Rosettes, Nos
    Interventions
    Radiotherapy (RT); Chemotherapy Drug, Cancer - Physician's Choice; Non-Investigational Surgical Resection; Temozolomide; Tumor Tissue Sample; Blood Sample; Cerebrospinal Fluid (CSF) Sample
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-03-06
    Completion
    2032-03-31
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEmbryonal Tumor With Multilayered Rosettes; Embryonal Tumor With Multilayered Rosettes, Nos
    InterventionRadiotherapy (RT); Chemotherapy Drug, Cancer - Physician's Choice; Non-Investigational Surgical Resection; Temozolomide +3 more
    PhasePhase 2
    Registry statusRecruiting

  • Toripalimab Plus Actinomycin-D As Fist-Line Treatment for GTN with FIGO Score 7

    NCT06020755 · start 2024-12

    Registered record
    Registry ID
    NCT06020755
    Conditions
    Gestational Trophoblastic Neoplasia
    Interventions
    Toripalimab; Actinomycin-D
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-12
    Completion
    2025-08
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGestational Trophoblastic Neoplasia
    InterventionToripalimab; Actinomycin-D
    PhasePhase 2
    Registry statusRecruiting

  • A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib

    NCT06699472 · start 2024-10-31

    Registered record
    Registry ID
    NCT06699472
    Conditions
    Ewing Sarcoma; Myelosuppression
    Interventions
    Chemotherapy; Trilaciclib Injection [Cosela]
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-10-31
    Completion
    2027-09-30
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEwing Sarcoma; Myelosuppression
    InterventionChemotherapy; Trilaciclib Injection [Cosela]
    PhasePhase 2
    Registry statusRecruiting

  • Toripalimab Plus Actinomycin-D as Fist-Line Treatment for GTN With FIGO Score 5-6

    NCT06028672 · start 2023-09-12

    Registered record
    Registry ID
    NCT06028672
    Conditions
    Gestational Trophoblastic Neoplasia
    Interventions
    Toripalimab; Actinomycin-D
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2023-09-12
    Completion
    2025-08
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGestational Trophoblastic Neoplasia
    InterventionToripalimab; Actinomycin-D
    PhaseNot applicable
    Registry statusRecruiting

  • Clinical Trial for Patients With a Stage IV Childhood Renal Tumor, Comparing Upfront Vincristine, Actinomycin-D and Doxorubicin (Standard Arm) With Upfront Vincristine, Carboplatin and Etoposide (Experimental Arm)

    NCT03669783 · start 2023-02-03

    Registered record
    Registry ID
    NCT03669783
    Conditions
    Childhood Renal Tumor
    Interventions
    treatment Vincristin; treatment Actinomycin-D; treatment Doxorubicin; treatment Carboplatin; Etoposide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2023-02-03
    Completion
    2033-10-03
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChildhood Renal Tumor
    Interventiontreatment Vincristin; treatment Actinomycin-D; treatment Doxorubicin; treatment Carboplatin +1 more
    PhasePhase 3
    Registry statusRecruiting

  • Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma

    NCT05253495 · start 2022-02-01

    Registered record
    Registry ID
    NCT05253495
    Conditions
    Non-hodgkin Lymphoma; Hodgkin Lymphoma
    Interventions
    DOC Group B; Pv-COMRAD 1 and 2 Group B; Pv-R-CYM 1 and 2 Group B; DOC Group C; MAD CPR 1 and 2; Pv-R CYVE 1 and 2; Pv-R CYVE-MTX 1 and 2; MAD CP; Pv-Cytarabine/etoposide; AD CP; Bv-AVD-R 1 and 2: COHORT IIa; Bv-NVD-R, Cycle 1-2; Bv-NVD-R, Cycle 1-4 SER; Bv-AVD-R; Bv-NVD-R, Cycle 1-4 RER; Bv-NAVD-R, Cycle 1-2; Involved Site Radiation Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2022-02-01
    Completion
    2028-06-30
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-hodgkin Lymphoma; Hodgkin Lymphoma
    InterventionDOC Group B; Pv-COMRAD 1 and 2 Group B; Pv-R-CYM 1 and 2 Group B; DOC Group C +13 more
    PhasePhase 2
    Registry statusRecruiting

  • Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia

    NCT05139095 · start 2022-01-27

    Registered record
    Registry ID
    NCT05139095
    Conditions
    Gestational Trophoblastic Neoplasia
    Interventions
    Camrelizumab plus apatinib CohortA; Camrelizumab plus apatinib Cohort B
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2022-01-27
    Completion
    2027-01-01
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGestational Trophoblastic Neoplasia
    InterventionCamrelizumab plus apatinib CohortA; Camrelizumab plus apatinib Cohort B
    PhasePhase 2
    Registry statusRecruiting

  • Improving Public Cancer Care by Implementing Precision Medicine in Norway

    NCT04817956 · start 2021-04-01

    Registered record
    Registry ID
    NCT04817956
    Conditions
    Cancer Metastatic
    Interventions
    Atezolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2021-04-01
    Completion
    2045-04-30
    Enrolment
    3,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer Metastatic
    InterventionAtezolizumab
    PhasePhase 2
    Registry statusRecruiting

  • A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg

    NCT04332874 · start 2020-04-01

    Registered record
    Registry ID
    NCT04332874
    Conditions
    Sarcoma; Myxofibrosarcoma; Undifferentiated Pleomorphic Sarcoma; Alveolar Soft Part Sarcoma
    Interventions
    Isolated Limb Infusion; Pembrolizumab; infusion of melphalan and dactinomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2020-04-01
    Completion
    2027-04-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma; Myxofibrosarcoma; Undifferentiated Pleomorphic Sarcoma; Alveolar Soft Part Sarcoma
    InterventionIsolated Limb Infusion; Pembrolizumab; infusion of melphalan and dactinomycin
    PhasePhase 2
    Registry statusRecruiting

  • Combination Therapy of Anthracyclines for Children With Nephroblastoma

    NCT03892330 · start 2019-06-01

    Registered record
    Registry ID
    NCT03892330
    Conditions
    0.5-14 Year Old Children With Nephroblastoma
    Interventions
    Vincristine; Oxytetracycline/ Cyclophosphamide; Liposomal doxorubicin; Doxorubicin; Pharmorubicin; Pirarubicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2019-06-01
    Completion
    2045-06-30
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    Condition0.5-14 Year Old Children With Nephroblastoma
    InterventionVincristine; Oxytetracycline/ Cyclophosphamide; Liposomal doxorubicin; Doxorubicin +2 more
    PhasePhase 4
    Registry statusNot yet recruiting